Trial reportAnnals of the rheumatic diseases2023
BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.
Abstract readClinical TrialLetter
In one paragraph
Trial report in Annals of the rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Pathogenesis exploration of lgG4-related disease: From the traditional central dogma and its remodeling perspective.Chinese medical journal · 2026Review
- Synergistic Interaction Between MALAT1/miR-30b-5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab-Refractory NMOSD.CNS neuroscience & therapeutics · 2026Article
- From 'Me too' to 'Me better' and 'Me cooler': the recent rheumatology advances in China.EULAR rheumatology open · 2026Review
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
- [Research progress on the application of telitacicept in rheumatism and autoimmune diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Real-world study of telitacicept in the treatment of IgA nephropathy.Frontiers in immunology · 2026Article
- Purpura as the initial manifestation of IgG4-related disease with concomitant systemic lupus erythematosus: a case report.Frontiers in medicine · 2026Article
- Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept.Molecular and cellular pediatrics · 2025Article
- Omics in IgG4-related disease.Chinese medical journal · 2025Review
- Effects of telitacicept in SLE patients with antiphospholipid antibody positivity: a retrospective self-controlled case series.Clinical rheumatology · 2025Article
- IgG4-related disease and other fibro-inflammatory conditions.Nature reviews. Rheumatology · 2025Review
- Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review.Frontiers in immunology · 2025Review
- Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series.Journal of inflammation research · 2025Article
- Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link.Frontiers in immunology · 2025Review
- [Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.Clinical kidney journal · 2024Article
- Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study.Therapeutic advances in neurological disorders · 2024Article
- The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.Drug design, development and therapy · 2024Review
- Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Shaozhe Cai *Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0001-6778-9745
Ziwei Hu *Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0003-3552-2143
Yu Chen *Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0002-7142-8851
Yuxue ChenDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0002-6010-8588
Bingxia MingDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0003-4861-4864
Rongfen GaoDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0002-5741-0874
Zhen LiDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Cong YeDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China tjhdongll@163.com zhongjixin620@163.com yecong2011@163.com.ORCID 0000-0001-5478-7361
Jixin ZhongDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China tjhdongll@163.com zhongjixin620@163.com yecong2011@163.com.ORCID 0000-0002-3534-7480
Lingli DongDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China tjhdongll@163.com zhongjixin620@163.com yecong2011@163.com.ORCID 0000-0003-2017-1125
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Autoimmune DiseasesImmunoglobulin G4-Related DiseaseGlucocorticoidsHumansProspective StudiesRecombinant Fusion ProteinsTumor Necrosis Factor Ligand Superfamily Member 13GlucocorticoidsRecombinant Fusion ProteinstelitaciceptTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13Autoimmune DiseasesB-LymphocytesGlucocorticoids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.